More importantly, based on the clinical data (Patients 3 and 6), the expression of PD‐1 in CD8+ T cells could be more predictive and suitable than the CPS for identifying GC patients who will respond effectively to anti‐PD‐1 therapy. This evidence concerns the gene PDCD1 and gastric cancer.